霉酚酸酯对哮喘小鼠骨髓CD34+造血细胞的干预作用

目的：研究新型免疫抑制剂霉酚酸酯对哮喘小鼠骨髓CD34^＋造血细胞生物活性的影响。并与糖皮质激素比较．探讨其潜在的治疗哮喘的机制及可能性。方法：以卵白蛋白（OVA）致敏并激发BALB／c小鼠建立哮喘模型。连续激发2周期间分为3组，每组6只，分别给予生理盐水（对照，A组）、泼尼松（B组）及霉酚酸酯（C组）灌胃．末次激发后24h分别取支气管肺泡灌洗液（BALF）、外周血及骨髓，测定BALF、外周血中有核细胞的分类计数及骨髓中有核细胞总数：ELISA方法测定外周血中IL-5水平；流式细胞仪测定外周血及骨髓中CD34^＋造血细胞、CD4^＋T淋巴细胞占有核细胞的比例：免疫组化结合原位杂交法检测骨髓内表达白细胞介素5（IL-5）受体α链mRNA的CD34^＋造血细胞（CD34^＋IL-5Rα mRNA^＋细胞）计数。结果：B、C组哮喘小鼠BALF中细胞总数、EOS计数，外周血中CD34^＋造血细胞计数及外周血中IL-5水平均低于A组相应指标．且差异有显著性（均P〈0．05）；C组BALF及外周血巾EOS计数、骨髓中CD34^＋造血细胞计数及CD34^＋IL-5RαmRNA＋细胞计数与B组相应指标比较，差异有显著性（均P〈0．05）。结论：霉酚酯酸（MMF）可能抑制嗜酸粒细胞（EOS）、T淋巴细胞的肺内浸润，抑制CD34^＋造血细胞从骨髓迁移至外周血，它可能主要通过抑制淋巴细胞增殖，减少IL-5的产生．来影响骨髓EOS祖细胞的分化。     

Relationship between bone marrow-derived CD34+ cells expressing interleukin-5 receptor messenger RNA and asthmatic airway inflammation

Background Asthma is clinically related with the degree of eosinophilic inflammation.How asthmatic airway inflammation is affected is still poorly understood. So the effects of bone marrow-derived hematopoietic cells expressing CD34 (CD34+) and interleukin-5 (IL-5) receptor messenger RNA (IL-5R mRNA+) on asthmatic airway inflammation were investigated.Methods Balb/c mice were sensitized and challenged by ovalbumin (OVA) to establish an asthmatic model while control mice were sensitized and exposed to sterile saline. The mice were killed at different time points after being challenged by OVA and sterile saline. Then, bronchoalveolar lavage fluid (BALF), peripheral blood (PB) and bone marrow (BM) were prepared. Eosinophils in PB (PBEOS) and BALF (BALFEOS), nuclear cells in BALF, PB and BM were counted. By flow cytometry, the percentage of CD34+ cells to nucleated cells in PB, BM and the relative number of CD34+ cells in PB (PBCD34+) and BM (BMCD34+) were calculated. Immunocytochemistry and in situ hybridization were used to investigate the hematopoietic cells with co-localized expression of CD34 and IL-5R mRNA in BM (BMCD34+IL-5R mRNA+). The percentage of BMCD34+IL-5R mRNA+ to BMCD34+ was calculated. Results Twelve hours after challenge by OVA, BALFEOS and PBEOS in the experimental group were significantly higher than those in the control group （P<0.01). Twenty-four hours after OVA challenge, BALFEOS, PBEOS and BMCD34+IL-5R mRNA+ were elevated maximally, significantly different from those in the control group （P<0.01). Forty-eight hours after OVA challenge, BALFEOS and BMCD34+IL-5R mRNA+ were still significantly higher than those of the controls （P<0.01). The other markers reverted to normal. In 60 mice, BMCD34+IL-5R mRNA+ was closely correlated with the BALEOS, PBEOS, BMCD34+ and BMCD34+ （%) （P<0.05).Conclusions The amount of CD34+ cells expressing IL-5R mRNA increased in the BM of asthmatic model mice, which favors eosinophilopoiesis and eosinophilic airway inflammation. A signal pathway exists between the lungs and the bone marrow, which is involved in the initiation and maintenance of asthmatic airway inflammation.     

骨髓增生异常综合征中骨髓CD34~+、CD34~-细胞凋亡和增殖的实验研究

目的:分析骨髓增生异常综合征(MDS)患者骨髓CD34+细胞和CD34-细胞凋亡和增殖情况,从该角度探讨MDS的发病机制。方法:流式细胞术分析20例高危MDS、20例低危MDS患者及10例正常对照者骨髓CD34+细胞的比例,CD34+细胞和CD34-细胞凋亡、增殖的百分率,计算各组中的凋亡/增殖(A/P)比。结果:(1)MDS患者CD34+细胞的比例明显高于对照组,其中高危组CD34+细胞的比例明显高于低危组(P<0.05),而低危组与对照组比较无显著差异;(2)CD34+,CD34-细胞的凋亡率在MDS低危组中均为最高,明显高于MDS高危组和对照组,在低危组中,CD34-细胞的凋亡率(80.36±1.82)%明显高于CD34+细胞(54.75±2.18)%(P<0.05),而在高危组中,CD34+,CD34-细胞的凋亡率无显著差异;(3)CD34+细胞的增殖率在MDS高危组中最高,明显高于低危组和对照组,而CD34-细胞的增殖率在MDS高危和低危组间无显著差异,在高危组中,CD34+细胞的增殖率(50.67±3.37)%明显高于CD34-细胞的(30.99±1.96)%(P<0.05);(4)无论CD34+,CD34-细胞的A/P值在MDS低危组中均明显高于高危组和正常对照组,而在MDS各亚组中,CD34-细胞的A/P值明显高于CD34+的A/P值(P<0.05)。结论:CD34+细胞百分率随MDS危险度增加而逐渐增加,在低危组中以CD34-细胞的凋亡占主导,随着病情进展,在高危组中则以CD34+细胞的增殖占主导,提示异常的凋亡和增殖在MDS的发生和发展中起重要作用。     

Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure

Background

Endothelial progenitor cells (EPC) which are characterised by the simulateous expression of CD34, CD133 and vascular endothelial growth receptor 2 (VEGF 2) are involved in the pathophysiology of congestive heart failure (CHF) and their number and function is reduced in CHF. But so far our knowledge about the number of circulating hematopoietic stem/progenitor cells (CPC) expressing the early hematopoietic marker CD133 and CD34 in CHF is spares and therefore we determined their number and correlated them with New York Heart Association (NYHA) functional class.

Methods

CD34 and CD133 surface expression was quantified by flow cytometry in the peripheral venous blood of 41 healthy adults and 101 patients with various degrees of CHF.

Results

CD34+, CD133+ and CD34+/CD133+ cells correlated inversely with age. Both the number of CD34+ and of CD34+/CD133+ cells inversely correlated with NYHA functional class. The number of CD133+ cells was not affected by NYHA class. Furthermore the number of CD133+ cells did not differ between control and CHF patients.

Conclusion

In CHF the release of CD34+, CD133+ and CD34+/CD133+ cells from the bone marrow seems to be regulated differently. Modulating the releasing process in CHF may be a tool in CHF treatment.     

G-CSF动员的外周血与骨髓CD34+细胞黏附分子的表达

目的：研究黏附分子在外周血干细胞动员机制中的作用。 方法：应用流式细胞仪检测粒细胞集落刺激因子G-CSF动员的外周血细胞与骨髓CD34⁺细胞表达的黏附分子非常延迟抗原4(VLA-4)、淋巴细胞功能相关抗原1(LFA-1)和L-选择素(CD62L)。 结果：G-CSF动员后的外周血CD34⁺细胞表达的VLA-4、LFA-1与骨髓CD34⁺细胞相比明显减少,CD62L无明显改变。 结论：黏附分子VLA-4及LFA-1降低可能是G-CSF动员造血干细胞进入外周血过程中的一个重要环节。     

抑制性消减杂交技术检测骨髓CD34+细胞基因差异表达

目的 检测、比较骨髓和动员外周血2种来源不同的CD34+细胞基因表达的差异。方法 从一健康供者分别获取骨髓和动员外周血,分离出CD34+细胞,利用抑制性消减杂交技术检测、比较该2种来源不同的CD34+细胞的基因表达差异。结果在骨髓CD34+细胞中共有21个基因高表达,主要涉及2类:（1）与细胞周期S期、G2期和M期转化相关的基因;（2）C/EBP（CCAAT/增强子结合蛋白）转录因子家族。结论骨髓和外周血CD34+细胞在基因表达上具有明显的不同,大部分骨髓CD34+细胞处于S期、G2期和M明,提示骨髓CD34+细胞比外周血CD34+增殖活跃。     

CD34抗原在小鼠造血基质细胞的表达及其意义

目的 了解造血基质细胞CD34抗原的表达情况并探讨其可能的意义。方法 用RT－PCR、斑点杂交和原位杂交的方法检测了BALB／C小鼠骨髓原代培养的基质细胞、传代培养的基质细胞及小鼠胚胎基质细胞系NIH3T3细胞CD34的表达。结果 传代培养的小鼠骨髓基质细胞CD34为强阳性表达，原代培养的骨髓基质细胞则表达很弱，NIH3T3细胞的表达强度介于前两者之间。结论 造血基质细胞也有强弱不等的CD34抗原的表达，其表达量的差别是否可能与造血基质细胞的增殖能力、细胞组成及其体外支持造血的能力等相关，有待进一步研究证实。     

脐血CD34~+细胞体外短期培养扩增研究

为寻找更有效的体外扩增脐血CD34 + 细胞的造血细胞因子组合 ,采集健康产妇脐带血 ,用免疫磁珠法分选CD34 + 细胞。采用SCF、FLT3 L、TPO和IL 34种具有早期作用的细胞因子的不同组合进行脐血CD34 + 细胞短期无血清液体培养 ,观察培养前后有核细胞、CD34 + 细胞、CD34 + /CD38- 细胞、CFU GEMM、CFU GM和BFU E数量的变化。结果在 3种不同的细胞因子组合中 ,同时应用SCF、FLT3 L、TPO和IL 34种细胞因子培养 7d的扩增效果最好。突出的发现是在这种条件下CD34 + /CD38- 细胞亚群达到平均 1 97.9倍的扩增效果。提示 :SCF、FLT3 L、TPO和IL 34种细胞因子是脐血CD34 + 细胞体外扩增理想的细胞因子组合     

免疫磁珠法分离骨髓CD34~+细胞的方法研究

目的 探讨免疫磁珠法分离CD34 细胞的方法. 方法 应用密度梯度离心法分离骨髓单一核细胞,后采用免疫磁珠法从单一核细胞中分选出CD34 细胞,流式细胞仪鉴定其纯度. 结果 各样品分离出的CD34 细胞占骨髓单一核细胞含量的(2.19±0.12)%,经流式细胞仪鉴定应用免疫磁珠分离的CD34 细胞纯度为(94.6±2.1)%. 结论 免疫磁珠法是分离CD34 细胞较理想的方法.     

骨髓增生异常综合征患者骨髓CD34+细胞亚群及其表面造血因子受体的表达

目的 探讨骨髓增生异常综合征(MDS)患者骨髓CD34+细胞亚群及其表面干细胞因子受体(SCF-R)、红细胞生成素受体(EpoR)、粒细胞集落刺激因子受体(G-CSFR)及血小板生成素受体(TpoR)的表达情况及其意义.方法 采用流式细胞术检测2008年7月至2010年3月天津医科大学总医院新诊断的45例MDS患者(17例低危患者、28例高危患者)及30名对照组原代骨髓CD34+CD38+及CD34+CD38-细胞亚群及其表面SCF-R、EpoR、G-CSFR及TpoR的表达率.结果 高危组CD34+细胞比例[0.53%(0.10%～1.68%)]明显高于对照组[0.13%(0.08%～0.32%),P＜0.01],其他2组间比较差异无统计学意义.低危组和高危组CD34+CD38+细胞比例(86.3%±8.5%、82.6%±11.1%)显著低于对照组(92.3%±3.4%,均P＜0.05),而CD34+CD38-细胞比例(13.7%±8.5%、17.4%±11.0%)显著高于对照组(7.7%±3.4%,均P＜0.05).对照组骨髓CD34+CD38+细胞亚群EpoR表达率(18.7%±18.3%)显著低于CD34+CD38-细胞亚群(63.6%±20.0%,P＜0.01),两亚群之间SCF-R、G-CSFR及TpoR表达率差异无统计学意义.在CD34+CD38+细胞亚群中,3组间SCF-R和TpoR表达率差异无统计学意义,而低危组和高危组EpoR的表达率[9.0%(1.4%～12.7%)、5.2%(1.1%～14.1%)]明显低于对照组[9.6%(5.1%～30.1%),均P＜0.05],G-CSFR的表达率(29.8%±19.1%、28.7%±21.1%)明显低于对照组(44.4%±23.4%,均P＜0.05);在CD34+CD38-细胞亚群中,3组间SCF-R和G-CSFR表达率差异无统计学意义,低危组和高危组EpoR的表达率(42.2%±21.9%、25.7%±15.6%)明显低于对照组(63.6%±20.0%,均P＜0.01),TpoR的表达率(5.4%±4.7%、4.1%±4.0%)明显低于对照组(10.1%±8.3%,均P＜0.05).MDS患者骨髓CD34+CD38+和CD34+CD38-细胞亚群表面受体表达率低的患者其外周血血红蛋白水平、中性粒细胞及血小板计数减低的发生率明显高于受体表达率不低的患者(均P＜0.05).结论 MDS患者的原代骨髓CD34+细胞亚群分化异常,膜表面部分造血细胞因子受体表达减低,这可能与MDS患者血细胞减少有关,有望用于辅助诊断MDS.

Abstract：

Objective To detect the abnormalities of differentiation and expression of membrane hemopoietic cytokine receptors on CD34 + bone marrow cells in patients with myelodysplastic syndromes (MDS). Methods Forty-five newly diagnosed MDS cases from July 2008 to March 2010 in our hospitaland 30 normal controls were enrolled. There were 17 low-risk and 28 high-risk patients. The CD34 + CD38 +and CD34 + CD38- bone marrow cells and the expressions of stem cell factor receptor (SCF-R),erythropoietin receptor (EpoR), granulocyte colony-stimulating factor receptors (G-CSFR) and thrombopoietin receptor (TpoR) on those cells were measured by flow cytometry. Results The mean percentage of CD34+ in karyocyte of MDS cases in high-risk patients [0. 53% (0. 10% - 1.68% )] was significantly higher than that of control group [0. 13% ( 0. 08% - 0. 32% ), P ＜ 0. 01] . The mean percentages of CD34 + CD38 + cells were significantly lower in low and high-risk groups (86. 3% ± 8.5% and 82. 6% ± 11.1% ) than those in control group (92. 3% ± 3.4% ). And the percentage of CD34+ CD38-cells was significantly higher in either low-risk or high-risk group ( 13.7% ±8. 5% and 17.4% ± 11.0% )than that in control group (7.7% ± 3.4%, both P ＜ 0. 05 ). In control group, the mean percentage of antigen expression of EpoR was significantly lower in CD34 + CD38 + cells than that in CD34 + CD38 - cells ( 18.7% ± 18. 3% vs 63. 6% ±20. 0%, P ＜0. 01 ). The expressions of SCF-R, G-CSFR and TpoR were not significantly different between two cell populations. The expressions of EpoR on CD34 + CD38 + cells of low and high-risk MDS groups [9.0% ( 1.4% - 12. 7% ), 5. 2% ( 1.1% - 14. 1% )] were significantly lower than those of control group [9. 6% (5.1% - 30. 1% ), both P ＜ 0. 05]. The expressions of G-CSFR on CD34+CD38+ cells of low and high-risk MDS groups (29.8% ± 19. 1%, 28.7% ± 21.1%) were significantly lower than those of control group (44.4% ± 23.4%, both P ＜ 0. 05 ). The quantities of EpoR on CD34 + CD38 - cells of low and high-risk MDS groups ( 42. 2% ± 21.9%, 25.7% ± 15. 6% ) were significantly lower than those of control group ( 63. 6% ± 20. 0%, both P ＜ 0. 01 ). The expressions of TpoR on CD34+ CD38- cells of low and high-risk MDS groups (5.4% ± 4.7%, 4.1% ± 4.0%) were significantly lower than those of control group ( 10. 1% ± 8. 3%, both P ＜ 0. 05 ). The incidence of cytopenia with low expression rates of hemopoietic cytokine receptors on CD34 + cells was higher than that of MDS with high expression rates. Conclusion The abnormalities of differentiation and membrane hemopoietic cytokine receptors expression of CD34 + bone marrow cells in MDS are associated with MDS cytopenia and may be useful for the diagnosis of MDS.     

不同组合方式的细胞因子对人骨髓AC133+和CD34+细胞增殖的影响

目的：探讨细胞因子不同的组合方式对人骨髓CD34⁺富集细胞及AC133⁺富集细胞体外扩增潜能的影响。方法：常规富集人骨髓CD34⁺及AC133⁺细胞,应用本研究组设计并已经证实的细胞因子组合方式,对人骨髓CD34⁺及AC133⁺富集细胞进行体外对照培养,分别观察CD34⁺和AC133⁺富集细胞的扩增情况;应用甲基纤维素半固体培养法,观察不同组别培养7、14、21d CD34⁺和AC133⁺富集细胞的集落形成情况及细胞凋亡率。结果：AC133⁺细胞实验组在相同条件下细胞扩增倍数以及集落生成数目上均明显高于CD34⁺细胞实验组,相同条件下细胞凋亡率明显低于CD34⁺细胞实验组。结论：AC133⁺细胞包含有更多原始的造血干细胞,AC133作为造血干细胞抗原标记明显优于CD34。     

动员的外周血干/祖细胞中P21的表达与CD34+细胞的相关性

目的检测动员的外周血干/祖细胞中P21的表达及与CD34+细胞的相关性,探讨其在动员过程中的变化及意义.方法选取异基因外周血干细胞移植正常供者9例和自体外周血干细胞移植者(急性白血病患者)6例,运用流式细胞术检测动员的外周血干/祖细胞中CD34+细胞及其亚群,用免疫细胞化学的方法检测外周血动员前后P21的表达.结果动员的外周血干/祖细胞中P21的表达明显高于动员前,二者间差异有统计学意义(P<0.05);动员的外周血干/祖细胞中CD34+细胞比例与P21的表达率呈正相关(r=0.553).结论外周血干/祖细胞动员过程中P21表达增高,可能与其促进祖细胞增殖、调控分化过程及抗凋亡活性有关.     

成人骨髓间充质干细胞对脐血CD34+细胞的体外扩增作用

目的: 探讨骨髓间充质干细胞(MSCS)对脐血CD34 细胞体外扩增作用. 方法: 分离培养成人MSCS作为滋养层,联合SCF, IL-11和GM-CSF分别组成对脐血CD34 细胞的不同扩增体系,培养3 wk后观察脐血有核细胞、CFCs以及CD34 细胞扩增倍数的变化. 结果: MSCS联合细胞因子组较其他组培养体系对有核细胞总数、CFCs含量及CD34 细胞含量均具有明显的扩增作用,分别扩增了114.2±2.4, 40.5±8.6, 11.3±0.4 倍. 结论: 成人MSCS协同其他细胞因子可增强脐血CD34 细胞的体外扩增作用.     

免疫磁珠法纯化小鼠CD34+造血干细胞

目的探讨免疫磁珠法(MiniMACS)能否用于纯化小鼠骨髓CD34+造血干细胞.方法应用免疫磁珠纯化小鼠骨髓CD34+细胞,流式细胞仪(FACS)评估纯化效率,检测纯化后的细胞活力.结果纯化后CD34+细胞纯度81.5%(范围76.80%～85.38%),回收率47.54%(范围40.50%～54.31%),纯化前后细胞活力不受影响(P=0.169).结论应用MiniMACS纯化小鼠骨髓可获得高纯度CD34+细胞,并不影响细胞活力.     

不同细胞因子对脐血CD34+细胞扩增的影响

目的探讨不同细胞因子促进脐血CD34 细胞扩增的效应,为下一步的临床应用奠定基础。方法采用EasySep免疫磁珠阳性选择系统分离脐血中CD34 细胞,在无血清、无基质细胞培养体系中添加不同细胞因子培养2周,分组:A组,SCF FL TPOB组,SCF FL TPO IL-3C组,SCF FL TPO G-CSF。结果CD34 细胞数目于培养后7d达到峰值,3组间差异无显著性;B组扩增至14d时细胞总数达(384.40±17.48)倍,显著高于另外2组。扩增7d后的脐血细胞经体外培养可形成造血集落。结论体外扩增脐血CD34 细胞理想的细胞因子组合为SCF TPO FL,以7d为宜。     

化疗+G-CSF方法动员外周血干细胞时骨髓及外周血相关细胞亚群的动态变化

目的探讨应用化疗 G-CSF方法动员外周血干细胞时,恶性血液病患者的骨髓及外周血CD34 细胞和T细胞亚群的变化特点.方法 16例拟行自体外周血干细胞移植患者,在应用化疗 G-CSF方法动员外周血干细胞期间,应用流式细胞仪测定骨髓及外周血CD34 和T细胞亚群动态变化情况.结果 1.恶性血液病患者在应用G-CSF前,骨髓中CD34 细胞的初始值为(0.52±0.31)%.应用G-CSF 48 h后,CD34 细胞测定值为(1.22±0.42)%,较前有明显增加(P＜0.001).CD34 细胞的高峰值出现在应用G-CSF 96 h后,为(2.23±0.34)%,较未应用G-CSF时差异显著(P＜0.001).2.恶性血液病患者在应用G-CSF前,外周血CD34 细胞测定值为(0.39±0.27)%.在应用G-CSF 72 h后外周血中CD34 细胞的测定值为(1.29±0.64)%,较前有明显增加(P＜0.001).应用G-CSF96 h后,CD34 细胞的测定值达高峰,为(1.41±0.73)%,较未应用G-CSF前差异显著(P＜0.001).3.无论是否应用G-CSF,恶性血液病患者的T淋巴细胞亚群比例均处于倒置状态,应用G-CSF后随CD34 细胞的逐渐增加,T淋巴细胞亚群变化不明显(P＞0.05).结论恶性血液病患者,在应用化疗 G-CSF动员外周血干细胞时,其骨髓及外周血CD34 细胞和T细胞亚群的动态变化各有其特点.     

氨茶碱、地塞米松对哮喘患者CD4+CD25+T调节细胞抑制功能的影响

目的探讨哮喘患者CD4+ CD25+ T调节细胞的作用是否存在缺陷及药物(地塞米松、小剂量氨茶碱)对其作用的影响,为有效控制哮喘提供依据。方法分离哮喘患者及健康对照者外周血CD4+ CD25+ T调节细胞及CD4+CD25-T淋巴细胞并培养,设CD4+ CD25+ T调节细胞组、CD4+CD25-T淋巴细胞组及CD4+ CD25+ T调节细胞联合CD4+CD25-T淋巴细胞组,第3组又分为氨茶碱干预组、地塞米松干预组及空白对照组,72h后取培养上清液用ELISA法检测IFN-γ、IL-5、IL-13水平。结果健康对照者CD4+ CD25+ T调节细胞可抑制IFN-γ、IL-5及IL-13的生成(P<0.01),哮喘患者仅抑制IFN-γ、IL-5的生成(P<0.01);地塞米松预处理CD4+ CD25+ T调节细胞后,健康对照者CD4+ CD25+ T调节细胞抑制IFN-γ(P<0.05)、IL-5(P<0.01)、IL-13(P<0.01)生成能力增强,哮喘患者抑制IL-5、IL-13生成能力增强(P<0.01);采用氨茶碱预处理后,健康对照者CD4+ CD25+ T调节细胞抑制IL-5(P<0.01)、IL...     

胚胎与成人骨髓CD34~+细胞RUNX1相关基因及Notch信号通路的比较研究

目的 了解引产儿胚胎与成人骨髓CD34+细胞生物学活性,寻找新的造血干细胞来源RUNX1相关基因和Notch信号通路差异.方法 RT-PCR检测引产儿胚胎和成人骨髓CD34+细胞RUNX1、Hes-1、SLC9A3R1、Notch1、Notch2、HLA-C、PDCD1、PKC-βI的mRNA表达水平.结果 引产儿胚胎骨髓CD34+细胞RUNX1、Hes-1、SLC9A3R1、Notch1、Notch2、HLA-C、PDCD1和PKC-βI的mRNA表达水平与成人组比较差异均无统计学意义(P>0.05).结论 引产儿胚胎骨髓CD34+细胞具有与成人骨髓CD34+细胞相似的生物学活性,可以作为实验中正常对照使用,满足实验需要.     

电离辐射对小鼠骨髓造血干/祖细胞中CD47表达的影响

探讨X射线全身照射后小鼠骨髓造血干/祖细胞（HSCs/HPCs）损伤和其中CD47表达水平的变化,初步阐明CD47在HSCs/HPCs电离辐射损伤中发挥的作用。     

脐血CD34+造血干细胞来源的树突状细胞体外培养体系的优化

目的：优化脐血CD34^＋造血干细胞（HPC）来源的树突状细胞（DCs）诱导培养方法，为体外研究CD34^＋HPC诱导产生功能性树突状细胞（DCs）的影响因素奠定基础。方法：淋巴细胞分离液（Ficoll）分离获得脐血单个核细胞，免疫磁珠阳性分选CD34^＋HPC，并用流式细胞术鉴定CD34^＋HPC纯度：比较GT（GM-CSF＋TNF—α）方案和GTI（GM—CSF＋TNF—α＋IL-4）方案及GTI方案中TNF—α．和IL-4不同时段加入对诱导培养产生的DCs成熟的影响：通过激光共聚焦显微镜观察细胞形态，流式细胞仪分析细胞表型及3H—TdR检测DCs激发异体T细胞增殖能力。结果：免疫磁珠阳性分选CD34＋HPC纯度可达90％以上：将CD34＋HPC按GT方案和GTI方案进行培养，均可诱导产生DCs．但经GT方案诱导的DCsCD14表达较高，CD80、CD86、CD83、CD1a表达不如经GTI方案诱导的高；而GTI方案中，以TNF—α．0h加入、IL-448h加入诱导培养的DCs各表型表达相对较佳．并具有激发异体T细胞增殖能力。结论：CD34^＋HPC经过合适的培养体系能够诱导分化为功能性DCs，以GM—CSF与TNF-α 0h加入、IL-448h加入的GM—CSF＋TNF—α＋IL-4方案更为可取。